UCB stock: TD Cowen sets EUR 305.00 target for UCB stock

Published on 10/19/2026 at 15:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB's 52-week range is EUR 197.45 to EUR 289.50. UCB stock costs EUR 204.40 on October 19, 2026, up 0.39 percent versus the Xetra close.

Analyst target and price position

TD Cowen listed a EUR 305.00 target for UCB on October 12, 2026.
UCB's 52-week range runs from EUR 197.45 to EUR 289.50.
UCB stock costs EUR 204.40 at Lang & Schwarz on October 19, 2026 at 5:07 p.m. CEST, 0.39 percent above the Xetra close of October 16, 2026.
UCB has a EUR 38.9 billion market capitalization and a P/E ratio of 17.68.

Moderner Biopharma-Forschungscampus mit Glasgebäuden und Laborpersonal in Brüssel bei Tageslicht — UCB S.A. mit ISIN BE0003739530 zeigt modernen Forschungscampus in Brüssel mit Laborpersonal in Glasgebäuden, Illustration mit AI erstellt.

TD Cowen listed a EUR 305.00 12-month target for UCB on October 12, 2026, according to Investing.com. Against the Lang & Schwarz price of EUR 204.40, that target is 49.27 percent above the price. UCB stock was trading at EUR 204.40 at Lang & Schwarz on October 19, 2026 at 5:07 p.m. CEST, 0.39 percent above the Xetra close of October 16, 2026 at EUR 203.60.

UCB remains near its yearly low

The stock's 52-week range is EUR 197.45 to EUR 289.50, based on market data dated October 19, 2026. The current price is 29.38 percent below the 52-week high and 3.52 percent above the 52-week low. That positioning makes the lower end of the range more relevant than the headline target for short-term price framing.

UCB's October 19 trading snapshot included a EUR 204.30 bid and a EUR 204.50 ask. Trading volume stood at 28,223 shares, compared with an average volume of 243,017 shares. The price therefore moved only modestly relative to the broader one-year range.

Valuation and upcoming reporting date

UCB had a market capitalization of EUR 38.9 billion and a trailing P/E ratio of 17.68 as of October 19, 2026. UCB's investor page describes the company as a biopharmaceutical group focused on neurology and immunology, while its first-half 2026 product figures include EUR 1.52 billion in BIMZELX sales, according to UCB.

Investing.com lists 19 analysts in its consensus and an average 12-month target of EUR 285.00. The same page lists TD Cowen's EUR 305.00 target dated October 12, 2026. A further reporting date shown by Barron's is February 25, 2027 for fiscal-year 2026 earnings.

Comparison with peers

UCB: plus 0.39 percent, P/E 17.68, market capitalization EUR 38.9 billion

argenx (Euronext Brussels, EUR): plus 0.19 percent, P/E 31.43, market capitalization EUR 45.8 billion

UCB's valuation sits below argenx's P/E on the October 19 market snapshot, while the two companies have similar market values.

What the price position means

The analyst target provides a forward-looking reference, but the market price remains close to UCB's 52-week low. The next clearly dated reporting marker is February 25, 2027, leaving the current valuation and the company's product sales as the main figures for assessing the stock's position.

UCB stock was trading at EUR 204.40 at Lang & Schwarz on October 19, 2026 at 5:07 p.m. CEST, up 0.39 percent versus the Xetra close of October 16, 2026 at EUR 203.60. The further course of trading is shown by the continuously updated real-time quote of UCB stock.